The modified vaccinia virus Ankara (MVA)-based live attenuated monkeypox vaccine, independently developed by Shanghai Institute of Biological Products Co (SIBP) under China National Pharmaceutical ...

About the GeoVax MVA Platform GeoVax’s vaccine platform utilizes modified vaccinia Ankara (MVA), a large virus capable of carrying several vaccine antigens, that expresses proteins that assemble into ...

has issued a Notice of Allowance for Patent Application No. 18/394,555 titled "Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) and Matrix Protein ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Nairobi — Health Cabinet Secretary Aden Duale has called on Kenyans to remain vigilant and strictly adhere to public health ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer ...

The new vaccine is a replication-deficient vaccine based on a modified vaccinia Ankara (MVA) strain ... candidate was safe ...

Kenya will soon launch its first Mpox vaccination campaign in 13 counties to prevent transmission of the virus.This follows the arrival of 10,700 doses of the Modified Vaccinia Ankara-Bavarian ...